The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options

Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER +) breast cancer. ER can be activated in a ligand-dependent and independent manner. Currently available ER-targeting agents include selective estrogen receptor modulators (SERMs), selective estrogen receptor degra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yating, Tang, Shou-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560885/
https://www.ncbi.nlm.nih.gov/pubmed/36229710
http://dx.doi.org/10.1007/s10555-022-10066-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560885/
https://www.ncbi.nlm.nih.gov/pubmed/36229710
http://dx.doi.org/10.1007/s10555-022-10066-y

Ejemplares similares